Tag: biotechnology
-
Biotechs Collaborate on Immunotherapies in $1.2B Deal
Two biotechnology companies developing cancer therapies harnessing the immune system are partnering on new treatments for solid tumor and blood-related cancers.
-
Biotech, Univ. Lab Partner on Stem Cells for Alzheimer’s
A biotechnology company specializing in stem cell therapeutics is licensing a process from Texas A&M University to produce exosomes — cellular delivery packages — from adult stem cells as possible therapies for Alzheimer’s disease.
-
Radiation, Biotech Companies Partner on Scar Therapy
Two companies taking different approaches to treating keloids — visible raised skin scars — are integrating their therapies to develop an anticipated treatment that removes and prevents the recurrence of these scars.
-
Pharma Maker Crowdsourcing for Drug Delivery Partners
The global pharmaceutical company AstraZeneca is looking for collaborators to develop treatments for disease using nucleic acids delivered with cell-penetrating peptides.
-
Engineered T-Cells Show Extended Leukemia Remission
A clinical trial shows a patient’s immune system cells, modified to add cancer-fighting proteins, can extend high remission among children with a type of leukemia for as long as 12 months, but also with high rates of adverse effects.
-
Report: 19 New Precision Medicines Approved in 2017
A report on Food and Drug Administration approvals of new therapies says the agency is accelerating its reviews of treatments designed to address the specific molecular composition of individuals.
-
Grants Made to Commercialize Bone, Cancer Research
A program supporting research with commercial potential awarded grants to scientists studying stem cells for bone grafts, treatments for melanoma, and protein therapies for cancer that change gene expression patterns.
-
Energy Dept Grant Funding Poplar Tree Rust Study
A university-government biotechnology lab is studying the genomics of leaf rust, a fungus afflicting poplar trees, an emerging biofuel crop, with the goal of engineering resistance to the pathogen.
-
Sanofi Buys Nano-Antibody Biotech in $4.8B Deal
Global drug maker Sanofi is acquiring a Belgian biotechnology company developing synthetic nanoscale therapeutic antibodies in a deal valued at $4.8 billion.
-
Biotech, Pharma Dominate U.S. Academic Patents
In 2016, patents on biotechnology, pharmaceuticals, and medical technologies accounted for 40 percent of all academic patents, with measurement technologies and organic chemistry each getting 7 percent of the total.